Javier Szwarcberg
Chief Executive Officer en SPRUCE BIOSCIENCES, INC. .
Fortuna: 84 354 $ al 31/03/2024
Perfil
Javier Szwarcberg is currently the Chief Executive Officer & Director at Spruce Biosciences, Inc. Prior to this, he worked as the VP, Head-Product & Portfolio Management at BioMarin Pharmaceutical, Inc. from 2020 to 2022, Senior VP-Program & Portfolio Management at Ultragenyx Pharmaceutical, Inc. from 2017 to 2020, and Vice President-Clinical & Business Development at Horizon Therapeutics Plc from 2016 to 2017.
He holds a doctorate degree from Universidad de Buenos Aires and a graduate degree from Harvard T.H.
Chan School of Public Health.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SPRUCE BIOSCIENCES, INC.
0.26% | 25/03/2024 | 107 321 ( 0.26% ) | 84 354 $ | 31/03/2024 |
Cargos activos de Javier Szwarcberg
| Empresas | Cargo | Inicio |
|---|---|---|
| SPRUCE BIOSCIENCES, INC. | Chief Executive Officer | 03/01/2022 |
Antiguos cargos conocidos de Javier Szwarcberg.
| Empresas | Cargo | Fin |
|---|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/01/2022 |
| ULTRAGENYX PHARMACEUTICAL INC. | Corporate Officer/Principal | 01/02/2020 |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Chief Tech/Sci/R&D Officer | 01/10/2017 |
Formación de Javier Szwarcberg.
| Universidad de Buenos Aires | Doctorate Degree |
| Harvard T.H. Chan School of Public Health | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 3 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ULTRAGENYX PHARMACEUTICAL INC. | Health Technology |
| SPRUCE BIOSCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
- Bolsa de valores
- Insiders
- Javier Szwarcberg
